Genetic diversity within leukemia-associated immunophenotype-defined subclones in AML.
F Tiso1, T N Koorenhof-Scheele1, E Huys1
1Department of Laboratory Medicine, Laboratory of Hematology, Radboudumc, Nijmegen, The Netherlands.
Annals of Hematology
|January 13, 2022
Summary
Combining immunophenotyping and genetic sequencing in acute myeloid leukemia (AML) provides a more complete understanding of the disease. These complementary techniques reveal crucial details about malignant cell populations that single methods may miss.
Area of Science:
- Hematology
- Molecular Biology
- Cancer Genomics
Background:
- Acute myeloid leukemia (AML) is a complex blood cancer characterized by significant heterogeneity and clonal evolution.
- Understanding the genetic makeup of distinct leukemic subclones is crucial for effective treatment strategies.
- Current diagnostic approaches often rely on immunophenotyping and genetic analysis, but their combined utility in characterizing AML subclones is not fully elucidated.
Purpose of the Study:
- To investigate the complementary roles of immunophenotyping and error-corrected sequencing of driver genes in characterizing distinct subclones within AML patients.
- To determine if combining these techniques provides a more comprehensive view of disease heterogeneity and clonal architecture compared to using either method alone.
Main Methods:
- Error-corrected sequencing of 27 myeloid leukemia driver genes was performed on 86 FACS-sorted normal and aberrant cell fractions from 10 AML patients.
- Immunophenotypic characterization was conducted on the same cell fractions to identify distinct subfractions.
- Comparative analysis was performed to assess the information gained from each technique and their combination.
Main Results:
- Three scenarios were identified: 1) both techniques equally characterized the malignancy, 2) immunophenotyping missed genetically aberrant subclones, and 3) genetic analysis missed mutations present in immunophenotypically defined malignant populations.
- In several cases, immunophenotypically normal-appearing cells harbored significant genetic mutations, highlighting the limitations of relying solely on immunophenotyping.
- Conversely, some immunophenotypically defined malignant populations lacked detectable mutations via sequencing, indicating potential limitations in genetic analysis sensitivity or clonal representation.
Conclusions:
- Immunophenotyping and molecular genetic analyses offer complementary information for characterizing acute myeloid leukemia.
- A parallel application of both immunophenotyping and molecular techniques is recommended for a comprehensive understanding of AML heterogeneity and clonal evolution.
- Integrating these approaches can lead to more accurate disease assessment and potentially improved therapeutic decisions in AML management.
Related Concept Videos
01:15Differentiation of Common Myeloid Progenitor Cells
3.4K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.4K
02:50Combination Therapies and Personalized Medicine
5.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K